Status:
TERMINATED
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
Lead Sponsor:
Cell Genesys
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to ho...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate
- Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy
- Detectable metastases
- Any Gleason score
- ECOG performance status 0-2
Exclusion
- Prior treatment with chemotherapy
- Prior Immunotherapy
- Prior treatment with gene therapy
- Significant cancer related pain
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
626 Patients enrolled
Trial Details
Trial ID
NCT00089856
Start Date
July 1 2004
End Date
October 1 2008
Last Update
November 5 2008
Active Locations (126)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Alabama Oncology, LLC
Alabaster, Alabama, United States, 35007
2
Alaska Clinical Research Center
Anchorage, Alaska, United States, 99508
3
Palo Verde Hematology/Oncology
Glendale, Arizona, United States, 85304
4
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States, 85259